Johnson & Johnson (NYSE:JNJ) is pulling the plug on its troubled metal-on-metal hip implant business, effective Aug. 31.
In a statement released by JNJ subsidiary DePuy Orthopaedics, the healthcare giant said it would halt all sales of its Ultamet metal-on-metal articulation and Complete ceramic-on-metal acetabular hip system because of lower physician adoption rates and a recent decision by the FDA to reclassify all metal-on-metal hip replacements.
MassDevice.com reported Johnson & Johnson’s decision was not related to safety concerns, despite a string of high-profile recalls of metal-on-metal hips by DePuy and other orthopedic device makers.
“The decision to discontinue these products is not related to safety or efficacy, and is not a recall,” company officials said in a prepared release. “Ultamet and Complete are backed by clinical data showing they are safe and effective options for patients who are candidates for hip replacement. As with all of our products, DePuy will continue to closely monitor the performance of Ultamet and Complete. DePuy reviews performance data from a variety of sources, including published and unpublished data from national joint registries, published literature, company-sponsored clinical trials and internal complaint data. This includes the FDA’s industry wide post-market surveillance of metal-on-metal hip systems.”
DePuy officials said the company will discontinue other products over the next year and a half as it continues to “simplify and streamline DePuy’s portfolio by focusing on fewer, worldwide strategic product platforms that meet patient and clinician needs and ensure long-term growth.”